EGFR and adenocarcinoma: Of those 249 IA patients, EGFR mutations were most common in papillary-predominant (83.87%) and lepidic-predominant adenocarcinoma (83.78%), followed by acinar-predominant (66.88%) and solid-predominant carcinoma (0.00%) (Figure 2C).